Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.58 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.58 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.58 |
| ▸ | CCR5 known ✓ | P51681 | 1/20 | 0.58 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.54 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.54 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.54 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.46 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.46 |
| ▸ | PSMD14 | O00487 | 5/20 | 0.95 |
| ▸ | COPS5 | Q92905 | 5/20 | 0.95 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | MMP2 | P08253 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30430691 | 1.00 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 | |
| SCHEMBL30079755 | 0.98 | PSMD14 (1.00) | PSMD14COPS5LMNAKDM4EMMP2 | |
| SCHEMBL536578 | 0.98 | PSMD14 (1.00) | PSMD14COPS5LMNAKDM4EMMP2 | |
| SCHEMBL1822441 | 0.95 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 | |
| SCHEMBL9221538 | 0.95 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 | |
| Hydrochloric Acid SCHEMBL23648281 | 0.95 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 | |
| SCHEMBL7333832 | 0.95 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 | |
| SCHEMBL7431585 | 0.95 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 | |
| SCHEMBL4819240 | 0.95 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 | |
| SCHEMBL27503149 | 0.95 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3003251-B1 | ANTIBACTERIAL POWDERS BASED ON ANIONIC SILICON OR TITANIUM DIOXIDE ADSORBED WITH PHARMACEUTICALLY ACTIVE CATIONS | PAVIA FARM S R L (IT) | 2019-07-10 | — | — | EP | claimed |
| EP-3004064-B1 | PHARMACEUTICAL COMPOSITIONS BASED ON PHOTOCHEMICALLY STABLE SILVER COMPLEXES, CHLOREXIDINE AND CATIONIC SURFACTANTS | PAVIA FARM S R L (IT) | 2017-11-01 | — | — | EP | claimed |
| US-20160130234-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON PHOTOCHEMICALLY STABLE SILVER COMPLEXES, CHLOREXIDINE AND CATIONIC SURFACTANTS | PAVIA FARMACEUTICI S.R.L. (IT) | 2016-05-12 | — | — | US | claimed |
| US-20160122367-A1 | ANTIBACTERIAL POWDERS BASED ON ANIONIC SILICON OR TITANIUM DIOXIDE ADSORBED WITH PHARMACEUTICALLY ACTIVE CATIONS | PAVIA FARMACEUTICI S.R.L. (IT) | 2016-05-05 | — | — | US | claimed |
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | claimed |
| EP-3004064-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON PHOTOCHEMICALLY STABLE SILVER COMPLEXES, CHLOREXIDINE AND CATIONIC SURFACTANTS | Pavia Farmaceutici S.r.l. (IT) | 2016-04-13 | — | — | EP | claimed |
| EP-3003252-A1 | ANIONIC SILICON DIOXIDE DERIVATIVES ADSORBED WITH PHARMACEUTICALLY ACTIVE CATIONS FOR DENTAL USE | Pavia Farmaceutici S.r.l. (IT) | 2016-04-13 | — | — | EP | claimed |
| WO-2014195764-A1 | ANIONIC SILICON DIOXIDE DERIVATIVES ADSORBED WITH PHARMACEUTICALLY ACTIVE CATIONS FOR DENTAL USE | PAVIA FARMACEUTICI S.R.L. (IT) | 2014-12-11 | — | — | WO | claimed |
| WO-2014195763-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON PHOTOCHEMICALLY STABLE SILVER COMPLEXES, CHLOREXIDINE AND CATIONIC SURFACTANTS | PAVIA FARMACEUTICI S.R.L. (IT) | 2014-12-11 | — | — | WO | claimed |
| US-8735586-B2 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI (FR) | 2014-05-27 | — | — | US | claimed |
| CN-101868447-A | Methods of making and administering quinoline derivatives as anticancer agents | UNIV HONG KONG POLYTECHNIC | 2010-10-20 | — | — | CN | claimed |
| US-20100261909-A1 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | claimed |
| US-20100216988-A1 | Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2010-08-26 | — | — | US | claimed |
| EP-2173721-A1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | claimed |
| EP-2173747-A1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | claimed |
| WO-2009024095-A1 | METHOD OF MAKING AND ADMINISTERING QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2009-02-26 | — | — | WO | claimed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | claimed |
| WO-2009000413-A1 | A REGIOSELECTIVE COPPER CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI-AVENTIS (FR) | 2008-12-31 | — | — | WO | claimed |
| WO-2009000412-A1 | A REGIOSELECTIVE METAL CATALYZED SYNTHESIS OF ANNELATED BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI AVENTIS (FR) | 2008-12-31 | — | — | WO | claimed |
| EP-0403524-B1 | PREPARATION OF NITRURO COMPOUNDS USABLE AS RADIO-PHARMACEUTICAL PRODUCTS | CIS BIO INTERNATIONAL (FR) | 1993-02-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130234-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON PHOTOCHEMICALLY STABLE SILVER COMPLEXES, CHLOREXIDINE AND CATIONIC SURFACTANTS | LAGE3, TP53RK, CAT | HSP90AA1 3032/4885MMP8 4421/4885MMP13 4751/4885 |
| US-20160122367-A1 | ANTIBACTERIAL POWDERS BASED ON ANIONIC SILICON OR TITANIUM DIOXIDE ADSORBED WITH PHARMACEUTICALLY ACTIVE CATIONS | SLC11A2, MSN, CUTA | HSP90AA1 1917/4885MMP8 874/4885MMP13 2571/4885 |
| US-20100261909-A1 | Regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles | AZI2, NISCH, UQCRB | HSP90AA1 2189/4885MMP8 4078/4885MMP13 4076/4885 |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | HCCS, GLS2, NQO1 | HSP90AA1 2647/4885MMP8 2350/4885MMP13 3044/4885 |
| US-20100216988-A1 | Regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles | AZI2, NIT2, NISCH | HSP90AA1 2074/4885MMP8 4062/4885MMP13 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.